NCT04814615 is a Phase 2 clinical trial of 89Zr-daratumumab PET/CT in Multiple Myeloma, sponsored by Hoag Memorial Hospital Presbyterian.

Who is sponsoring NCT04814615?

NCT04814615 is sponsored by Hoag Memorial Hospital Presbyterian.

What drugs are being tested in NCT04814615?

Interventions in NCT04814615: 89Zr-daratumumab PET/CT.

What condition does NCT04814615 study?

NCT04814615 studies Multiple Myeloma.

Is NCT04814615 still recruiting?

NCT04814615 is currently status unknown. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT04814615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Status unknown Phase 2 Last updated 27 June 2023

What this trial tests

Phase 2 trial testing 89Zr-daratumumab PET/CT in Multiple Myeloma in 60 participants. Status unknown.

Timeline

8 March 2021

Primary endpoint
31 January 2026

15 March 2026

Quick facts

Lead sponsor	Hoag Memorial Hospital Presbyterian
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	8 March 2021
Primary completion	31 January 2026
Estimated completion	15 March 2026
Sites	2 locations across United States

Drugs / interventions tested

89Zr-daratumumab PET/CT — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Hoag Memorial Hospital Presbyterian

Who can join

21 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho SF, Xing L, Anderson KC, Tai YT. · · 2021 · cited 28× · PMID 34885245 · DOI 10.3390/cancers13236136
CD38 as theranostic target in oncology.
Bocuzzi V, Bridoux J, Pirotte M, Withofs N, et al · · 2024 · cited 17× · PMID 39501292 · DOI 10.1186/s12967-024-05768-6
[Minimal residual disease assessment and progress in multiple myeloma].
Zhou HX, Chen WM. · · 2024 · cited 1× · PMID 38604801 · DOI 10.3760/cma.j.cn121090-20230728-00036

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Hoag Memorial Hospital Presbyterian trials

Trials by the same sponsor.

NCT06736054 — A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer · Phase 1 · recruiting
NCT05880394 — Study of Dotatate Imaging in Breast Cancer · Phase 2 · unknown
NCT04700332 — PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer · Phase 2 · recruiting
NCT04883814 — 18F-fluoroestradiol (FES) PET/CT for Breast Cancer · Phase 2 · unknown
NCT04750434 — PET MRI as a Staging Tool for Head and Neck Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04814615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoag Memorial Hospital Presbyterian
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04814615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing